Suven Pharmaceuticals Ltd
NSE:SUVENPHAR

Watchlist Manager
Suven Pharmaceuticals Ltd Logo
Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
Watchlist
Price: 1 259.15 INR -2.18% Market Closed
Market Cap: 320.5B INR
Have any thoughts about
Suven Pharmaceuticals Ltd?
Write Note

Suven Pharmaceuticals Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Suven Pharmaceuticals Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Suven Pharmaceuticals Ltd
NSE:SUVENPHAR
Capital Expenditures
-â‚ą517.9m
CAGR 3-Years
22%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Capital Expenditures
-â‚ą27.4B
CAGR 3-Years
-30%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Capital Expenditures
-â‚ą15.5B
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Capital Expenditures
-â‚ą19.4B
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Capital Expenditures
-â‚ą4.8B
CAGR 3-Years
-19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Capital Expenditures
-â‚ą3.9B
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Suven Pharmaceuticals Ltd
Glance View

Market Cap
320.5B INR
Industry
Pharmaceuticals

Suven Pharmaceuticals Ltd. manufactures chemical products. The company is headquartered in Hyderabad, Telangana and currently employs 1,193 full-time employees. The company went IPO on 2020-03-09. The firm operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe and Rest of the World. In India, the Company sells bulk drugs and intermediates, fine chemicals and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In Rest of the World, the Company sells bulk drugs, intermediates and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.

SUVENPHAR Intrinsic Value
402.41 INR
Overvaluation 68%
Intrinsic Value
Price

See Also

What is Suven Pharmaceuticals Ltd's Capital Expenditures?
Capital Expenditures
-517.9m INR

Based on the financial report for Mar 31, 2024, Suven Pharmaceuticals Ltd's Capital Expenditures amounts to -517.9m INR.

What is Suven Pharmaceuticals Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
2%

Over the last year, the Capital Expenditures growth was 82%. The average annual Capital Expenditures growth rates for Suven Pharmaceuticals Ltd have been 22% over the past three years , 2% over the past five years .

Back to Top